Cocrystal Pharma, INC. (COCP) — 8-K Filings

All 8-K filings from Cocrystal Pharma, INC.. Browse 32 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (32)

Cocrystal Pharma Files 8-K — Dec 18, 2025 Risk: low
Cocrystal Pharma, Inc. filed an 8-K on December 18, 2025, reporting under Regulation FD and including financial statements and exhibits. The company, incorporat
Cocrystal Pharma Files 8-K with Corporate Updates — Dec 1, 2025 Risk: low
Cocrystal Pharma, Inc. filed an 8-K on December 1, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the comp
Cocrystal Pharma Files 8-K: Material Agreement & Equity Sales — Oct 30, 2025 Risk: medium
Cocrystal Pharma, Inc. announced on October 28, 2025, the entry into a material definitive agreement. The company also disclosed unregistered sales of equity se
Cocrystal Pharma Files 8-K — Oct 27, 2025 Risk: low
Cocrystal Pharma, Inc. filed an 8-K on October 27, 2025, reporting information under Regulation FD and including financial statements and exhibits. The company,
Cocrystal Pharma Enters Material Agreement, Discloses Equity Sales — Sep 15, 2025 Risk: medium
Cocrystal Pharma, Inc. announced on September 12, 2025, the entry into a material definitive agreement. The company also disclosed unregistered sales of equity
Cocrystal Pharma Files 8-K — Sep 12, 2025 Risk: low
Cocrystal Pharma, Inc. filed an 8-K on September 12, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not conta
Cocrystal Pharma Files 8-K on Financials — Aug 14, 2025 Risk: low
Cocrystal Pharma, Inc. filed an 8-K on August 14, 2025, reporting on its results of operations and financial condition. The filing includes financial statements
Cocrystal Pharma Files 8-K with Corporate Updates — Aug 5, 2025 Risk: low
Cocrystal Pharma, Inc. filed an 8-K on August 5, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the compan
Cocrystal Pharma Files 8-K — Jul 10, 2025 Risk: low
Cocrystal Pharma, Inc. filed an 8-K on July 10, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, incorporated in D
Cocrystal Pharma 8-K: Security Holder Vote Matters — Jul 1, 2025 Risk: low
Cocrystal Pharma, Inc. filed an 8-K on June 25, 2025, reporting on matters submitted to a vote of its security holders. The filing details the company's corpora
Cocrystal Pharma Files 8-K with Bylaw Amendments — Jun 18, 2025 Risk: low
Cocrystal Pharma, Inc. filed an 8-K on June 18, 2025, reporting amendments to its Articles of Incorporation or Bylaws and filing financial statements and exhibi
Cocrystal Pharma Files 8-K — Jun 5, 2025 Risk: low
Cocrystal Pharma, Inc. filed an 8-K on June 5, 2025, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain spe
Cocrystal Pharma Files 8-K — May 29, 2025 Risk: low
Cocrystal Pharma, Inc. filed an 8-K on May 29, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain spe
Cocrystal Pharma Files 8-K with Corporate Updates — Apr 24, 2025 Risk: low
Cocrystal Pharma, Inc. filed an 8-K on April 24, 2025, reporting on Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the compa
Cocrystal Pharma Files 8-K: Updates and Former Names — Apr 23, 2025 Risk: low
Cocrystal Pharma, Inc. filed an 8-K on April 23, 2025, reporting on Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the compa
Cocrystal Pharma: Board & Executive Compensation Changes — Apr 8, 2025 Risk: medium
Cocrystal Pharma, Inc. announced on April 2, 2025, a change in its board of directors and executive compensation arrangements. The filing details the departure
Cocrystal Pharma Files 8-K — Apr 1, 2025 Risk: low
Cocrystal Pharma, Inc. filed an 8-K on April 1, 2025, reporting events as of March 31, 2025. The filing primarily concerns financial statements and exhibits, wi
Cocrystal Pharma Files 8-K — Jan 13, 2025 Risk: low
Cocrystal Pharma, Inc. filed an 8-K on January 13, 2025, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not cont
Cocrystal Pharma Files 8-K — Jan 8, 2025 Risk: low
On January 8, 2025, Cocrystal Pharma, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No
Cocrystal Pharma Files 8-K with Financials & Reg FD — Dec 31, 2024 Risk: low
Cocrystal Pharma, Inc. filed an 8-K on December 31, 2024, reporting on its financial statements and exhibits. The filing also includes a Regulation FD Disclosur
Cocrystal Pharma Files 8-K on Financials — Nov 13, 2024 Risk: low
Cocrystal Pharma, Inc. filed an 8-K on November 13, 2024, reporting on its results of operations and financial condition, as well as financial statements and ex
Cocrystal Pharma Files 8-K — Oct 31, 2024 Risk: low
Cocrystal Pharma, Inc. filed an 8-K on October 31, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain
Cocrystal Pharma Appoints New Director, Discloses Officer Compensation — Oct 10, 2024 Risk: medium
Cocrystal Pharma, Inc. announced on October 9, 2024, a change in its Board of Directors. Specifically, Dr. David S. Hong has been appointed as a new director, e
Cocrystal Pharma Files 8-K on Aug 19 Events — Aug 20, 2024 Risk: low
Cocrystal Pharma, Inc. filed an 8-K on August 20, 2024, reporting events as of August 19, 2024. The filing primarily concerns Regulation FD Disclosure and Finan
Cocrystal Pharma Files 8-K — Jul 18, 2024 Risk: low
On July 18, 2024, Cocrystal Pharma, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements/exhibits. No spec
Cocrystal Pharma Files 8-K on Corporate Changes — Jun 28, 2024 Risk: medium
Cocrystal Pharma, Inc. filed an 8-K on June 28, 2024, reporting on events that occurred on June 25, 2024. The filing indicates changes to its Articles of Incorp
Cocrystal Pharma Files 8-K — Jun 20, 2024 Risk: low
Cocrystal Pharma, Inc. filed an 8-K on June 20, 2024, reporting information under Regulation FD Disclosure and Financial Statements and Exhibits. The filing det
Cocrystal Pharma Files 8-K — May 1, 2024 Risk: low
Cocrystal Pharma, Inc. filed an 8-K on May 1, 2024, reporting information under Regulation FD Disclosure and Financial Statements and Exhibits. The company, for
Cocrystal Pharma Files 8-K — Mar 19, 2024 Risk: low
Cocrystal Pharma, Inc. filed an 8-K on March 19, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contai
Cocrystal Pharma Terminates Material Agreement — Mar 1, 2024 Risk: medium
Cocrystal Pharma, Inc. announced on February 28, 2024, the termination of a material definitive agreement. The company, incorporated in Delaware, filed this 8-K
Cocrystal Pharma Confirms Nasdaq Listing Under COCP — Jan 8, 2024
Cocrystal Pharma, Inc. filed an 8-K on January 8, 2024, primarily to disclose its registration on The Nasdaq Stock Market LLC under the trading symbol COCP. Thi
Cocrystal Pharma 8-K: General Corporate Info, Nasdaq Listing Confirmed — Jan 4, 2024
Cocrystal Pharma, Inc. filed an 8-K on January 4, 2024, primarily to disclose general corporate information and confirm its common stock, trading under the symb

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX